STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.